Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476038 | 0.81 | MAPT (0.40) | TDP1MEN1KMT2ATTRALB | |
| SCHEMBL2551316 | 0.79 | TDP1 (0.51) | TDP1MEN1KMT2ATTRALB | |
| SCHEMBL4468270 | 0.79 | PDE7A (0.58) | TDP1MEN1KMT2APDE7AGAA | |
| SCHEMBL2549702 | 0.76 | TDP1 (0.45) | TDP1MEN1KMT2ATTRALB | |
| SCHEMBL20605311 | 0.74 | ALDH1A1 (0.49) | TDP1MEN1KMT2APDE7AHTT | |
| SCHEMBL199649 | 0.74 | HSPB1 (0.54) | TDP1MEN1KMT2APDE7AMET | |
| SCHEMBL2550803 | 0.72 | NPC1 (0.42) | TDP1MEN1KMT2ATTRALB | |
| SCHEMBL1894479 | 0.71 | HTT (0.52) | MEN1KMT2APDE7AHTTGAA | |
| SCHEMBL21681366 | 0.69 | TDP1 (0.41) | TDP1MEN1KMT2ATTRALB | |
| SCHEMBL21681375 | 0.68 | MEN1 (0.75) | TDP1MEN1KMT2ATTRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-20160130256-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-20160130256-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-20160130256-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| EP-2556065-B1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-12-17 | — | — | EP | disclosed |
| EP-2556065-B1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-12-17 | — | — | EP | disclosed |
| EP-2556065-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2011121366-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011121366-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362208-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | TDP1 2420/4885MEN1 3387/4885KMT2A 2764/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | TDP1 940/4885MEN1 4419/4885KMT2A 2657/4885 |
| US-20160130256-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | TDP1 2420/4885MEN1 3387/4885KMT2A 2764/4885 |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | TDP1 1005/4885MEN1 4479/4885KMT2A 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.